| Code | CSB-RA006045MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Lenzilumab, designed to specifically target CSF2 (colony-stimulating factor 2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). CSF2 is a critical cytokine that regulates the proliferation, differentiation, and activation of myeloid cells including granulocytes, macrophages, and dendritic cells. This protein plays a central role in inflammatory responses and immune regulation, with dysregulated CSF2 signaling implicated in various pathological conditions including acute respiratory distress syndrome (ARDS), cytokine release syndrome, rheumatoid arthritis, and certain malignancies. Elevated GM-CSF levels have been associated with severe inflammatory states and autoimmune disorders.
Lenzilumab is a humanized IgG1 kappa monoclonal antibody that neutralizes GM-CSF by preventing its interaction with cell surface receptors. This biosimilar provides researchers with a valuable tool for investigating CSF2-mediated signaling pathways, studying myeloid cell biology, and exploring therapeutic mechanisms in inflammation-driven diseases. It is particularly useful for preclinical studies examining cytokine modulation and immune cell function in disease models.
There are currently no reviews for this product.